A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia B

Interventions

DRUG: REGV131
DRUG: LNP1265

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]